Orgenesis Inc. (ORGS)
Company Description
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide.
The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network.
It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient.
The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011.
Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Country | United States |
IPO Date | Mar 13, 2012 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 146 |
CEO | Vered Caplan M.Sc. |
Contact Details
Address: 20271 Goldenrod Lane Germantown, Maryland United States | |
Website | https://www.orgenesis.com |
Stock Details
Ticker Symbol | ORGS |
Exchange | OTC |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001460602 |
CUSIP Number | 68619K204 |
ISIN Number | US68619K2042 |
Employer ID | 98-0583166 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Vered Caplan M.Sc. | Chairperson of the Board, Chief Executive Officer & President |
Dr. Shimon Hassin Ph.D. | Chief Technology Officer |
Victor Miller | Chief Financial Officer, Secretary & Treasurer |
Prof. Sarah Ferber Ph.D. | Founder & Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 01, 2025 | NT 10-K | Filing |
Mar 18, 2025 | 3 | Filing |
Mar 14, 2025 | SCHEDULE 13G | Filing |
Mar 06, 2025 | 8-K | Current Report |
Jan 28, 2025 | 8-K | Current Report |
Dec 27, 2024 | 8-K | Current Report |
Dec 16, 2024 | 4 | Filing |
Dec 16, 2024 | 4 | Filing |
Dec 16, 2024 | 4 | Filing |
Dec 16, 2024 | 4 | Filing |